Volume 14 Supplement 2
Abstracts from the International Symposium HIV and Emerging Infectious Diseases 2014
Meeting abstracts
Publication of this supplement has been funded by the Overcome Agency.
International Symposium HIV and Emerging Infectious Diseases 2014. Go to conference site.
Marseille, France21-23 May 2014
Page 3 of 3
-
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P83
-
Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P84 -
Evaluation of diagnostic efficiency of the new enzyme immunoassay for detection of IgM antibodies to Hepatitis B core antigen
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P85 -
Prevalence and molecular characterization of Hepatitis B in HIV infected individuals in Botswana
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P86 -
Sexual transmission of Hepatitis C virus between HIV infected subjects and their main heterosexual partners; Actor Partner Interdependent Modelling
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P87 -
Hepatitis C diagnosics: clinical evaluation of the HCV-core antigen determination
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P88 -
Antiviral treatment in severe acute hepatitis B
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P90 -
Hantaviruses: seroprevalence and risk factors among humans in Achaia prefecture, Greece
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P91 -
Paediatric PARV4 infection in South Africa: relationship to age, maternal PARV4 status, and HIV infection
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P92 -
HPV vaccination in HIV+ adolescents and young adults induces strong HPV-specific immune responses
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P93 -
Emerging virus coinfections of the CNS: HTLV I/II as a common denominator
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P94 -
Prevalence of Human Papilloma Virus in Tunisia
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P95 -
Use and acceptance of long lasting insecticidal net screens for dengue prevention in Acapulco, Guerrero, Mexico
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P96 -
Current clinico-mycological trends of onychopathies in Casablanca
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P97 -
High risk HPV genotypes in Belarus
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P98 -
Molecular diagnosis of cytomegalovirus, Epstein-Barr virus and Herpes virus 6 among blood donors in Ouagadougou, Burkina Faso
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P99 -
Hepatitis E virus seroprevalence in patients with HIV in Nizhny Novgorod, Russia
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P100 -
Functional properties of the novel PA-X endonuclease of human influenza virus
Citation: BMC Infectious Diseases 2014 14(Suppl 2):P101 -
Ten big challenges ahead
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S1 -
New ARV drugs
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S2 -
First Line Therapy in 2014
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S3 -
Switch strategies in 2014
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S4 -
Managing HCV infection: present and future
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S5 -
Improving prevention and early diagnosis
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S6 -
ART for prevention: opportunities, challenges and predictions
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S7 -
Implementation of TasP: challenges and opportunities
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S8 -
ARV regimen choice and co-morbidities
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S9 -
Statin use in setting of HIV infection
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S10 -
Development of long-acting ARV’s
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S11 -
Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S12 -
Is ART suspension never a good idea? - Cons
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S13 -
Is an HIV vaccine achievable? - Pros
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S14 -
New anti-HCV agents in the pipeline
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S15 -
Treatment of hepatitis C in HIV patients in the new DAA era
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S16 -
HCV cure without interferon
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S17 -
Update on HIV reservoirs
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S18 -
Gene therapy and bone marrow transplantation
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S19 -
Hepatitis E
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S20 -
H7N9 flu
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S21 -
MERS-CoV
Citation: BMC Infectious Diseases 2014 14(Suppl 2):S22
Annual Journal Metrics
-
Citation Impact
3.669 - 2-year Impact Factor (2021)
3.714 - 5-year Impact Factor (2021)
1.448 - SNIP (Source Normalized Impact per Paper)
1.042 - SJR (SCImago Journal Rank)Speed
16 days to first decision for all manuscripts (Median)
42 days to first decision for reviewed manuscripts only (Median)Usage
10,831,430 Downloads (2022)
28,243 Altmetric mentions (2021)
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication